HoneyNaps Expands AI-Driven Sleep Data Services for Clinical Trials

The transition toward automated sleep analysis addresses a critical bottleneck in medical research: the high variability often found in manual scoring across different institutions. HoneyNaps now provides objective quantification of physiological measures, including sleep stages, respiratory events, and arousals, through its SOMNUM technology. Having supported trials involving over 10,000 participants, the firm is leveraging this experience to offer tailored clinical endpoints for multicenter studies.

Taekyoung (Sean) Ha, PhD, president of HoneyNaps USA, noted that while research objectives differ across the pharmaceutical and medical device sectors, the demand for consistent, reproducible data remains a universal priority. By moving beyond simple scoring into comprehensive clinical analysis, the company aims to establish foundational evidence for future digital biomarkers. This expansion allows researchers to minimize institutional discrepancies, ensuring that treatment responses and device performance metrics are evaluated against uniform, high-fidelity criteria.